Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2010. The Company reported total revenue of $156.1 million for the third quarter, including net product sales of $154.0 million. GAAP net loss for the quarter ended September 30, 2010 was $50.7 million, or $0.35 per share compared to $26.7 million, or $0.19 per share for the same period in 2009. Net loss excluding restructuring charges of $6.0 million was $44.7 million for the quarter ended September 30, 2010. Non-GAAP operating loss was $16.1 million for the quarter ended September 30, 2010 compared to non-GAAP operating income of $0.6 million for the same period in 2009. For the nine months ended September 30, 2010 non-GAAP operating loss was $27.3 million, a 34% improvement over the $41.6 million non-GAAP operating loss for the same period in 2009. At September 30, 2010 the Company held cash, cash equivalents and short-term investments of $537.7 million.

"While disappointed about the complete response letter for BYDUREON, we are more committed than ever to working closely with the FDA to bring this important therapy to people with type 2 diabetes as quickly as possible," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals. "Our year-to-date reduction in non-GAAP operating loss reflects the financial discipline we have implemented across our organization. We are operating from a strong cash position and will continue to drive revenue from BYETTA and SYMLIN and control our expenses in order to deliver strong financial performance for our shareholders."

Third Quarter HighlightsHighlights of Amylin's third quarter and recent activities include:

  • Announced the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Applicat
    '/>"/>

  • SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
    5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
    8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
    10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
    (Date:1/22/2015)... 2015  Bio-Techne Corporation (NASDAQ: TECH ) announced ... of the new Simple Plex platform through its Proteins ... the re-branding of the previously acquired CyPlex instrument platform ... a transformative immunoassay technology which integrates an innovatively designed ...
    (Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( ... "Infectious Disease Diagnostics Market by Product, Application, Technology, End ... their offering. , The infectious disease diagnostics ... to reach $18,156.2 million by 2019 from $12,422.8 million ...
    Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
    ... Farr Air Pollution Control (APC) has produced a new ... Containment." U.S. and Canadian visitors can view the video ... www.camfilfarrapc.com/videos/29 . David Steil, pharmaceutical ... approach dust collection in the pharmaceutical industry to achieve ...
    ... Calif., Nov. 8, 2011 Molecular Devices, LLC, a ... research, and bioassay/test development, today announced the launch of ... benefit of measuring up to sixty-four samples per plate ... http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ) With the option to test ...
    Cached Medicine Technology:Molecular Devices Launches the MicroMax Low Volume Microplate, the Highest Throughput Low Volume Solution Available 2
    (Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
    (Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the basic ... , Purchasing an accidental death and dismemberment rider for a ... rider provides benefits if the insured dies in an accident. ... of life insurance. , AD&D is not expensive and ...
    (Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
    (Date:1/22/2015)... 22, 2015 EBSCO Information Services ... expanding their relationship in an effort to further promote visibility ... While EBSCO has long made AMA journals available via its ... for The JAMA Network. , Long known as ...
    (Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining ... for reducing the costs of an auto insurance policy . ... to get lower prices for their vehicle insurance policies. The safety ... determining policy costs. Because of this, drivers should always carry ...
    Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
    ... world wide, bad prognosis liver disease and characterized by ... previous work, p90RSK is observed significantly up-regulated in association ... fibrosis. But detail mechanism of this phenomenon is still ... to be published on May 7, 2009 in the ...
    ... VX2 carcinoma model by injecting the cell suspension of ... by X-ray fluoroscopy is feasible. The advantages of the ... high stability. The rectal VX2 carcinoma established in this ... aspects of pathological representation, tumor development, and metastasis. It ...
    ... receptor type B (NPR-B) gene was expressed in ... and the expression was increased in diabetic rats. ... is up-regulated and it may contribute to diabetic ... (delayed gastric emptying) is frequent in diabetic patients. ...
    ... RWD(R) Healthcare Practice to Streamline Patient Flow and Improve ... some hospitals are struggling financially, St. Luke,s Episcopal Hospital ... efficient patient care with quality at its core. In ... is streamlining its transfer process for patients who need ...
    ... Cystitis Epidemiology (RICE) study estimates prevalence of 3 to ... 13 Three to eight million women in the ... newly released prevalence number, presented at the 2009 American ... to 6 percent of all U.S. women. This ...
    ... , Women Face in their Romantic Relationships and ... From decreased intimacy to lack of communication with their ... relationships, according to a new study commissioned by ... nation,s leading non-profit addiction treatment centers.The survey, "Caron ...
    Cached Medicine News:Health News:A feasible, simple and convenient model for study of rectal carcinoma 2Health News:NPs-NPR-B/pGC-cGMP signal pathway is involved in diabetic gastroparesis 2Health News:St. Luke's Episcopal Hospital Announces Latest Phase of Efficiency, Excellence and Engagement Campaign 2Health News:St. Luke's Episcopal Hospital Announces Latest Phase of Efficiency, Excellence and Engagement Campaign 3Health News:St. Luke's Episcopal Hospital Announces Latest Phase of Efficiency, Excellence and Engagement Campaign 4Health News:Prevalence of Interstitial Cystitis in U.S. Much Larger Than Previously Believed 2Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 2Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 3Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 4Health News:New Study Shows Stresses of Economic Downturn on Women's Relationships 5
    Detection of Malarial antigen in Human whole blood....
    The KAT-Quick Malaria test was designed for the diagnosis of Malaria, in laboratories, the home and for medical kits when travelling into malaria regions....
    The Malaria Combo Test is a rapid test for the qualitative detection of Plasmodium falciparum and / or Plasmodium vivax , Plasmodium ovale and Plasmodium malariae antigen in whole blood. This ...
    Ultraview SL 3800...
    Medicine Products: